Early Diagnosis of Gastric Cancer Cachexia

Launched by XIJING HOSPITAL · Feb 18, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on finding a way to detect cachexia early in patients with gastric cancer. Cachexia is a serious condition that causes weight loss and muscle wasting, and it affects a large number of people with gastric cancer—up to 80% of them may experience it. The researchers are studying certain molecules found in the blood, called microRNAs, which may help identify patients at risk for developing cachexia before it becomes severe. The goal is to create a simple test kit that can help doctors diagnose this condition early, allowing for better treatment options.

To participate in this trial, patients must be diagnosed with gastric cancer and have complete medical records available. They should not have any other serious illnesses or mental health issues that would prevent them from participating. The trial is currently looking for participants aged 65 to 74, and both men and women are welcome to join. If eligible, participants can expect to provide blood samples for testing and help advance research that could improve care for future gastric cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with gastric cancer diagnosed by histopathology or cytopathology
• • 2. Complete clinical and pathological data
• • 3. No previous or current mental illness or disturbance of consciousness
• Exclusion Criteria:
• • 1. With multiple tumors or other malignant diseases
• • 2. Combined with other chronic wasting and metabolic diseases
• • 3. Past patients with non-tumor cachexia
• • 4. People with mental illness or unable to cooperate